EPO Revokes Controversial Patent For Breast Cancer Screening

Law360, New York (May 19, 2004, 12:00 AM EDT) -- The European Patent Office has revoked U.S. biotechnology company Myriad Genetics’ European patent on a controversial breast cancer genetic test that critics claim is excessively expensive.

The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.

“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.